Switching from ergot to nonergot dopamine agonists in Parkinson's disease: A clinical series and five‐drug dose conversion table
- 11 June 2004
- journal article
- research article
- Published by Wiley in Movement Disorders
- Vol. 19 (11) , 1370-1374
- https://doi.org/10.1002/mds.20210
Abstract
Of 99 patients on ergot-derived dopamine agonists informed about possible long-term side effects, switching to a nonergot was undertaken in 88 (89%). There were adverse events in 26%. After 11 months, 82% were on their switch agonist and 93% were on any agonist. Switching dopamine agonists is feasible in this population.Keywords
This publication has 17 references indexed in Scilit:
- Valvular Heart Disease in Patients Taking PergolideMayo Clinic Proceedings, 2002
- Switching from Bromocriptine to Ropinirole in Patients with Advanced Parkinson's Disease: Open Label Pilot Responses to Three Different Dose-RatiosClinical Neuropharmacology, 2001
- Switching from pergolide to pramipexole in patients with Parkinson's diseaseJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 2001
- A Five-Year Study of the Incidence of Dyskinesia in Patients with Early Parkinson's Disease Who Were Treated with Ropinirole or LevodopaNew England Journal of Medicine, 2000
- An overnight switch to ropinirole therapy in patients with Parkinson's diseaseJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1999
- Constrictive Pericarditis and Pleuropulmonary Disease Linked to Ergot Dopamine Agonist Therapy (Cabergoline) for Parkinson's DiseaseMayo Clinic Proceedings, 1999
- Retroperitoneal fibrosis caused by treatment with pergolide in a patient with Parkinson’s diseaseBritish Journal of Urology, 1998
- Cabergoline in Parkinson's disease complicated by motor fluctuationsMovement Disorders, 1996
- Retroperitoneal Fibrosis in a Patient with Parkinsonʼs Disease Treated with PergolideClinical Neuropharmacology, 1995
- Agonist substitution in advanced Parkinson's diseaseNeurology, 1989